APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Receptor ROR Gamma

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nuclear Receptor ROR Gamma Market Outlook and Growth Opportunities 2026

Report ID 174018080419 December 2025208 pages

Choose your research edition.

Industry ResearchNuclear Receptor ROR Gamma Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Receptor ROR Gamma Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Nuclear Receptor ROR Gamma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Receptor ROR Gamma Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Receptor ROR Gamma Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Nuclear Receptor ROR Gamma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nuclear Receptor ROR Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nuclear Receptor ROR Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nuclear Receptor ROR Gamma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nuclear Receptor ROR Gamma market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nuclear Receptor ROR Gamma market include Eli Lilly, GlaxoSmithKline Plc, Biogen Inc, Beijing Hanmi Pharmaceutical, Reata Pharmaceuticals Inc, Phenex Pharmaceuticals AG, Pfizer Inc, Lead Pharma Holding BV and Glenmark Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nuclear Receptor ROR Gamma market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nuclear Receptor ROR Gamma and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Receptor ROR Gamma sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nuclear Receptor ROR Gamma market size, projected growth trends, production technologies, key applications, and end-use industries.

Nuclear Receptor ROR Gamma Segment by Company

Eli Lilly

GlaxoSmithKline Plc

Biogen Inc

Beijing Hanmi Pharmaceutical

Reata Pharmaceuticals Inc

Phenex Pharmaceuticals AG

Pfizer Inc

Lead Pharma Holding BV

Glenmark Pharmaceuticals

Genfit SA

Eurofins Advinus

Celgene Corp

Bristol-Myers Squibb Company

Brickell Biotech Inc

Aurigene Discovery Technologies

AbbVie Inc

Nuclear Receptor ROR Gamma Segment by Type

BBI-6000

R&D Progress

INV-17

IMU-366

GSK-2981278

GRC-39815Action

Others

Nuclear Receptor ROR Gamma Segment by Application

Axial Spondyloarthritis

Asthma

Breast Cancer

Chronic Obstructive Pulmonary Disease

Others

Nuclear Receptor ROR Gamma Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nuclear Receptor ROR Gamma status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nuclear Receptor ROR Gamma market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nuclear Receptor ROR Gamma significant trends, drivers, influence factors in global and regions.

6. To analyze Nuclear Receptor ROR Gamma competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Receptor ROR Gamma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Receptor ROR Gamma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Receptor ROR Gamma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nuclear Receptor ROR Gamma market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Receptor ROR Gamma industry.

Chapter 3: Detailed analysis of Nuclear Receptor ROR Gamma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nuclear Receptor ROR Gamma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nuclear Receptor ROR Gamma in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nuclear Receptor ROR Gamma Industry Trends Table 2. Nuclear Receptor ROR Gamma Industry Drivers Table 3. Nuclear Receptor ROR Gamma Industry Opportunities and Challenges Table 4. Nuclear Receptor ROR Gamma Industry Restraints Table 5. Global Nuclear Receptor ROR Gamma Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nuclear Receptor ROR Gamma Revenue Share by Company (2021-2026) Table 7. Global Nuclear Receptor ROR Gamma Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Nuclear Receptor ROR Gamma Sales Volume Share by Company (2021-2026) Table 9. Global Nuclear Receptor ROR Gamma Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nuclear Receptor ROR Gamma Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nuclear Receptor ROR Gamma Key Company Manufacturing Base & Headquarters Table 12. Global Nuclear Receptor ROR Gamma Company, Product Type & Application Table 13. Global Nuclear Receptor ROR Gamma Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nuclear Receptor ROR Gamma by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of BBI-6000 Table 18. Significant Companies of R&D Progress Table 19. Significant Companies of INV-17 Table 20. Significant Companies of IMU-366 Table 21. Significant Companies of GSK-2981278 Table 22. Significant Companies of GRC-39815Action Table 23. Significant Companies of Others Table 24. Global Nuclear Receptor ROR Gamma Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Nuclear Receptor ROR Gamma Sales Volume by Type (2021-2026) & (W Units) Table 26. Global Nuclear Receptor ROR Gamma Sales Volume by Type (2027-2032) & (W Units) Table 27. Global Nuclear Receptor ROR Gamma Sales Volume Share by Type (2021-2026) Table 28. Global Nuclear Receptor ROR Gamma Sales Volume Share by Type (2027-2032) Table 29. Global Nuclear Receptor ROR Gamma Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Nuclear Receptor ROR Gamma Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Nuclear Receptor ROR Gamma Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Nuclear Receptor ROR Gamma Sales Value Share by Type (2021-2026) Table 33. Global Nuclear Receptor ROR Gamma Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Axial Spondyloarthritis Table 35. Significant Companies of Asthma Table 36. Significant Companies of Breast Cancer Table 37. Significant Companies of Chronic Obstructive Pulmonary Disease Table 38. Significant Companies of Others Table 39. Global Nuclear Receptor ROR Gamma Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Nuclear Receptor ROR Gamma Sales Volume by Application (2021-2026) & (W Units) Table 41. Global Nuclear Receptor ROR Gamma Sales Volume by Application (2027-2032) & (W Units) Table 42. Global Nuclear Receptor ROR Gamma Sales Volume Share by Application (2021-2026) Table 43. Global Nuclear Receptor ROR Gamma Sales Volume Share by Application (2027-2032) Table 44. Global Nuclear Receptor ROR Gamma Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Nuclear Receptor ROR Gamma Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Nuclear Receptor ROR Gamma Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Nuclear Receptor ROR Gamma Sales Value Share by Application (2021-2026) Table 48. Global Nuclear Receptor ROR Gamma Sales Value Share by Application (2027-2032) Table 49. Global Nuclear Receptor ROR Gamma Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 50. Global Nuclear Receptor ROR Gamma Sales by Region (2021-2026) & (W Units) Table 51. Global Nuclear Receptor ROR Gamma Sales Market Share by Region (2021-2026) Table 52. Global Nuclear Receptor ROR Gamma Sales by Region (2027-2032) & (W Units) Table 53. Global Nuclear Receptor ROR Gamma Sales Market Share by Region (2027-2032) Table 54. Global Nuclear Receptor ROR Gamma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Nuclear Receptor ROR Gamma Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Nuclear Receptor ROR Gamma Sales Value Share by Region (2021-2026) Table 57. Global Nuclear Receptor ROR Gamma Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Nuclear Receptor ROR Gamma Sales Value Share by Region (2027-2032) Table 59. Global Nuclear Receptor ROR Gamma Market Average Price (US$/Unit) by Region (2021-2026) Table 60. Global Nuclear Receptor ROR Gamma Market Average Price (US$/Unit) by Region (2027-2032) Table 61. Global Nuclear Receptor ROR Gamma Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 62. Global Nuclear Receptor ROR Gamma Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Nuclear Receptor ROR Gamma Sales by Country (2021-2026) & (W Units) Table 64. Global Nuclear Receptor ROR Gamma Sales Market Share by Country (2021-2026) Table 65. Global Nuclear Receptor ROR Gamma Sales by Country (2027-2032) & (W Units) Table 66. Global Nuclear Receptor ROR Gamma Sales Market Share by Country (2027-2032) Table 67. Global Nuclear Receptor ROR Gamma Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Nuclear Receptor ROR Gamma Sales Value Market Share by Country (2021-2026) Table 69. Global Nuclear Receptor ROR Gamma Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Nuclear Receptor ROR Gamma Sales Value Market Share by Country (2027-2032) Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Eli Lilly Nuclear Receptor ROR Gamma Product Portfolio Table 75. Eli Lilly Recent Development Table 76. GlaxoSmithKline Plc Company Information Table 77. GlaxoSmithKline Plc Business Overview Table 78. GlaxoSmithKline Plc Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. GlaxoSmithKline Plc Nuclear Receptor ROR Gamma Product Portfolio Table 80. GlaxoSmithKline Plc Recent Development Table 81. Biogen Inc Company Information Table 82. Biogen Inc Business Overview Table 83. Biogen Inc Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Biogen Inc Nuclear Receptor ROR Gamma Product Portfolio Table 85. Biogen Inc Recent Development Table 86. Beijing Hanmi Pharmaceutical Company Information Table 87. Beijing Hanmi Pharmaceutical Business Overview Table 88. Beijing Hanmi Pharmaceutical Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Beijing Hanmi Pharmaceutical Nuclear Receptor ROR Gamma Product Portfolio Table 90. Beijing Hanmi Pharmaceutical Recent Development Table 91. Reata Pharmaceuticals Inc Company Information Table 92. Reata Pharmaceuticals Inc Business Overview Table 93. Reata Pharmaceuticals Inc Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Reata Pharmaceuticals Inc Nuclear Receptor ROR Gamma Product Portfolio Table 95. Reata Pharmaceuticals Inc Recent Development Table 96. Phenex Pharmaceuticals AG Company Information Table 97. Phenex Pharmaceuticals AG Business Overview Table 98. Phenex Pharmaceuticals AG Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Phenex Pharmaceuticals AG Nuclear Receptor ROR Gamma Product Portfolio Table 100. Phenex Pharmaceuticals AG Recent Development Table 101. Pfizer Inc Company Information Table 102. Pfizer Inc Business Overview Table 103. Pfizer Inc Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Inc Nuclear Receptor ROR Gamma Product Portfolio Table 105. Pfizer Inc Recent Development Table 106. Lead Pharma Holding BV Company Information Table 107. Lead Pharma Holding BV Business Overview Table 108. Lead Pharma Holding BV Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Lead Pharma Holding BV Nuclear Receptor ROR Gamma Product Portfolio Table 110. Lead Pharma Holding BV Recent Development Table 111. Glenmark Pharmaceuticals Company Information Table 112. Glenmark Pharmaceuticals Business Overview Table 113. Glenmark Pharmaceuticals Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Glenmark Pharmaceuticals Nuclear Receptor ROR Gamma Product Portfolio Table 115. Glenmark Pharmaceuticals Recent Development Table 116. Genfit SA Company Information Table 117. Genfit SA Business Overview Table 118. Genfit SA Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Genfit SA Nuclear Receptor ROR Gamma Product Portfolio Table 120. Genfit SA Recent Development Table 121. Eurofins Advinus Company Information Table 122. Eurofins Advinus Business Overview Table 123. Eurofins Advinus Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Eurofins Advinus Nuclear Receptor ROR Gamma Product Portfolio Table 125. Eurofins Advinus Recent Development Table 126. Celgene Corp Company Information Table 127. Celgene Corp Business Overview Table 128. Celgene Corp Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Celgene Corp Nuclear Receptor ROR Gamma Product Portfolio Table 130. Celgene Corp Recent Development Table 131. Bristol-Myers Squibb Company Company Information Table 132. Bristol-Myers Squibb Company Business Overview Table 133. Bristol-Myers Squibb Company Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Bristol-Myers Squibb Company Nuclear Receptor ROR Gamma Product Portfolio Table 135. Bristol-Myers Squibb Company Recent Development Table 136. Brickell Biotech Inc Company Information Table 137. Brickell Biotech Inc Business Overview Table 138. Brickell Biotech Inc Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Brickell Biotech Inc Nuclear Receptor ROR Gamma Product Portfolio Table 140. Brickell Biotech Inc Recent Development Table 141. Aurigene Discovery Technologies Company Information Table 142. Aurigene Discovery Technologies Business Overview Table 143. Aurigene Discovery Technologies Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Aurigene Discovery Technologies Nuclear Receptor ROR Gamma Product Portfolio Table 145. Aurigene Discovery Technologies Recent Development Table 146. AbbVie Inc Company Information Table 147. AbbVie Inc Business Overview Table 148. AbbVie Inc Nuclear Receptor ROR Gamma Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. AbbVie Inc Nuclear Receptor ROR Gamma Product Portfolio Table 150. AbbVie Inc Recent Development Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. Nuclear Receptor ROR Gamma Distributors List Table 154. Nuclear Receptor ROR Gamma Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Nuclear Receptor ROR Gamma Product Image Figure 2. Global Nuclear Receptor ROR Gamma Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Receptor ROR Gamma Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nuclear Receptor ROR Gamma Sales (2021-2032) & (W Units) Figure 5. Global Nuclear Receptor ROR Gamma Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nuclear Receptor ROR Gamma Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. BBI-6000 Image Figure 10. R&D Progress Image Figure 11. INV-17 Image Figure 12. IMU-366 Image Figure 13. GSK-2981278 Image Figure 14. GRC-39815Action Image Figure 15. Others Image Figure 16. Global Nuclear Receptor ROR Gamma Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Nuclear Receptor ROR Gamma Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Nuclear Receptor ROR Gamma Sales Volume Share by Type (2021-2032) Figure 19. Global Nuclear Receptor ROR Gamma Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nuclear Receptor ROR Gamma Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Nuclear Receptor ROR Gamma Sales Value Share by Type (2021-2032) Figure 22. Axial Spondyloarthritis Image Figure 23. Asthma Image Figure 24. Breast Cancer Image Figure 25. Chronic Obstructive Pulmonary Disease Image Figure 26. Others Image Figure 27. Global Nuclear Receptor ROR Gamma Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Nuclear Receptor ROR Gamma Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Nuclear Receptor ROR Gamma Sales Volume Share by Application (2021-2032) Figure 30. Global Nuclear Receptor ROR Gamma Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Nuclear Receptor ROR Gamma Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Nuclear Receptor ROR Gamma Sales Value Share by Application (2021-2032) Figure 33. Global Nuclear Receptor ROR Gamma Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 34. Global Nuclear Receptor ROR Gamma Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Nuclear Receptor ROR Gamma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Nuclear Receptor ROR Gamma Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Nuclear Receptor ROR Gamma Sales Value (2021-2032) & (US$ Million) Figure 38. North America Nuclear Receptor ROR Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Nuclear Receptor ROR Gamma Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Nuclear Receptor ROR Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Nuclear Receptor ROR Gamma Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Nuclear Receptor ROR Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Nuclear Receptor ROR Gamma Sales Value (2021-2032) & (US$ Million) Figure 44. South America Nuclear Receptor ROR Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Nuclear Receptor ROR Gamma Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Nuclear Receptor ROR Gamma Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Nuclear Receptor ROR Gamma Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Nuclear Receptor ROR Gamma Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • BBI-6000
  • R&D Progress
  • INV-17
  • IMU-366
  • GSK-2981278
  • GRC-39815Action
  • Others
Applications
  • Axial Spondyloarthritis
  • Asthma
  • Breast Cancer
  • Chronic Obstructive Pulmonary Disease
  • Others
Companies covered
  • Eli Lilly
  • GlaxoSmithKline Plc
  • Biogen Inc
  • Beijing Hanmi Pharmaceutical
  • Reata Pharmaceuticals Inc
  • Phenex Pharmaceuticals AG
  • Pfizer Inc
  • Lead Pharma Holding BV
  • Glenmark Pharmaceuticals
  • Genfit SA
  • Eurofins Advinus
  • Celgene Corp
  • Bristol-Myers Squibb Company
  • Brickell Biotech Inc
  • Aurigene Discovery Technologies
  • AbbVie Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nuclear Receptor ROR Gamma Sales Value (2021-2032)
  4. 1.2.2 Global Nuclear Receptor ROR Gamma Sales Volume (2021-2032)
  5. 1.2.3 Global Nuclear Receptor ROR Gamma Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nuclear Receptor ROR Gamma Market Dynamics
  1. 2.1 Nuclear Receptor ROR Gamma Industry Trends
  2. 2.2 Nuclear Receptor ROR Gamma Industry Drivers
  3. 2.3 Nuclear Receptor ROR Gamma Industry Opportunities and Challenges
  4. 2.4 Nuclear Receptor ROR Gamma Industry Restraints
3 Nuclear Receptor ROR Gamma Market by Company
  1. 3.1 Global Nuclear Receptor ROR Gamma Company Revenue Ranking in 2025
  2. 3.2 Global Nuclear Receptor ROR Gamma Revenue by Company (2021-2026)
  3. 3.3 Global Nuclear Receptor ROR Gamma Sales Volume by Company (2021-2026)
  4. 3.4 Global Nuclear Receptor ROR Gamma Average Price by Company (2021-2026)
  5. 3.5 Global Nuclear Receptor ROR Gamma Company Ranking (2024-2026)
  6. 3.6 Global Nuclear Receptor ROR Gamma Company Manufacturing Base and Headquarters
  7. 3.7 Global Nuclear Receptor ROR Gamma Company Product Type and Application
  8. 3.8 Global Nuclear Receptor ROR Gamma Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nuclear Receptor ROR Gamma Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nuclear Receptor ROR Gamma Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nuclear Receptor ROR Gamma Market by Type
  1. 4.1 Nuclear Receptor ROR Gamma Type Introduction
  2. 4.1.1 BBI-6000
  3. 4.1.2 R&D Progress
  4. 4.1.3 INV-17
  5. 4.1.4 IMU-366
  6. 4.1.5 GSK-2981278
  7. 4.1.6 GRC-39815Action
  8. 4.1.7 Others
  9. 4.2 Global Nuclear Receptor ROR Gamma Sales Volume by Type
  10. 4.2.1 Global Nuclear Receptor ROR Gamma Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Nuclear Receptor ROR Gamma Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Nuclear Receptor ROR Gamma Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Nuclear Receptor ROR Gamma Sales Value by Type
  14. 4.3.1 Global Nuclear Receptor ROR Gamma Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Nuclear Receptor ROR Gamma Sales Value by Type (2021-2032)
  16. 4.3.3 Global Nuclear Receptor ROR Gamma Sales Value Share by Type (2021-2032)
5 Nuclear Receptor ROR Gamma Market by Application
  1. 5.1 Nuclear Receptor ROR Gamma Application Introduction
  2. 5.1.1 Axial Spondyloarthritis
  3. 5.1.2 Asthma
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Chronic Obstructive Pulmonary Disease
  6. 5.1.5 Others
  7. 5.2 Global Nuclear Receptor ROR Gamma Sales Volume by Application
  8. 5.2.1 Global Nuclear Receptor ROR Gamma Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Nuclear Receptor ROR Gamma Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Nuclear Receptor ROR Gamma Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Nuclear Receptor ROR Gamma Sales Value by Application
  12. 5.3.1 Global Nuclear Receptor ROR Gamma Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Nuclear Receptor ROR Gamma Sales Value by Application (2021-2032)
  14. 5.3.3 Global Nuclear Receptor ROR Gamma Sales Value Share by Application (2021-2032)
6 Nuclear Receptor ROR Gamma Regional Sales and Value Analysis
  1. 6.1 Global Nuclear Receptor ROR Gamma Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Receptor ROR Gamma Sales by Region (2021-2032)
  3. 6.2.1 Global Nuclear Receptor ROR Gamma Sales by Region: 2021-2026
  4. 6.2.2 Global Nuclear Receptor ROR Gamma Sales by Region (2027-2032)
  5. 6.3 Global Nuclear Receptor ROR Gamma Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nuclear Receptor ROR Gamma Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nuclear Receptor ROR Gamma Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nuclear Receptor ROR Gamma Sales Value by Region (2027-2032)
  9. 6.5 Global Nuclear Receptor ROR Gamma Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nuclear Receptor ROR Gamma Sales Value (2021-2032)
  12. 6.6.2 North America Nuclear Receptor ROR Gamma Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nuclear Receptor ROR Gamma Sales Value (2021-2032)
  15. 6.7.2 Europe Nuclear Receptor ROR Gamma Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nuclear Receptor ROR Gamma Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nuclear Receptor ROR Gamma Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nuclear Receptor ROR Gamma Sales Value (2021-2032)
  21. 6.9.2 South America Nuclear Receptor ROR Gamma Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nuclear Receptor ROR Gamma Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nuclear Receptor ROR Gamma Sales Value Share by Country, 2025 VS 2032
7 Nuclear Receptor ROR Gamma Country-level Sales and Value Analysis
  1. 7.1 Global Nuclear Receptor ROR Gamma Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nuclear Receptor ROR Gamma Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nuclear Receptor ROR Gamma Sales by Country (2021-2032)
  4. 7.3.1 Global Nuclear Receptor ROR Gamma Sales by Country (2021-2026)
  5. 7.3.2 Global Nuclear Receptor ROR Gamma Sales by Country (2027-2032)
  6. 7.4 Global Nuclear Receptor ROR Gamma Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nuclear Receptor ROR Gamma Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nuclear Receptor ROR Gamma Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nuclear Receptor ROR Gamma Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nuclear Receptor ROR Gamma Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nuclear Receptor ROR Gamma Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Nuclear Receptor ROR Gamma Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Nuclear Receptor ROR Gamma Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 Biogen Inc
  14. 8.3.1 Biogen Inc Company Information
  15. 8.3.2 Biogen Inc Business Overview
  16. 8.3.3 Biogen Inc Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Inc Nuclear Receptor ROR Gamma Product Portfolio
  18. 8.3.5 Biogen Inc Recent Developments
  19. 8.4 Beijing Hanmi Pharmaceutical
  20. 8.4.1 Beijing Hanmi Pharmaceutical Company Information
  21. 8.4.2 Beijing Hanmi Pharmaceutical Business Overview
  22. 8.4.3 Beijing Hanmi Pharmaceutical Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Beijing Hanmi Pharmaceutical Nuclear Receptor ROR Gamma Product Portfolio
  24. 8.4.5 Beijing Hanmi Pharmaceutical Recent Developments
  25. 8.5 Reata Pharmaceuticals Inc
  26. 8.5.1 Reata Pharmaceuticals Inc Company Information
  27. 8.5.2 Reata Pharmaceuticals Inc Business Overview
  28. 8.5.3 Reata Pharmaceuticals Inc Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Reata Pharmaceuticals Inc Nuclear Receptor ROR Gamma Product Portfolio
  30. 8.5.5 Reata Pharmaceuticals Inc Recent Developments
  31. 8.6 Phenex Pharmaceuticals AG
  32. 8.6.1 Phenex Pharmaceuticals AG Company Information
  33. 8.6.2 Phenex Pharmaceuticals AG Business Overview
  34. 8.6.3 Phenex Pharmaceuticals AG Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Phenex Pharmaceuticals AG Nuclear Receptor ROR Gamma Product Portfolio
  36. 8.6.5 Phenex Pharmaceuticals AG Recent Developments
  37. 8.7 Pfizer Inc
  38. 8.7.1 Pfizer Inc Company Information
  39. 8.7.2 Pfizer Inc Business Overview
  40. 8.7.3 Pfizer Inc Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc Nuclear Receptor ROR Gamma Product Portfolio
  42. 8.7.5 Pfizer Inc Recent Developments
  43. 8.8 Lead Pharma Holding BV
  44. 8.8.1 Lead Pharma Holding BV Company Information
  45. 8.8.2 Lead Pharma Holding BV Business Overview
  46. 8.8.3 Lead Pharma Holding BV Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lead Pharma Holding BV Nuclear Receptor ROR Gamma Product Portfolio
  48. 8.8.5 Lead Pharma Holding BV Recent Developments
  49. 8.9 Glenmark Pharmaceuticals
  50. 8.9.1 Glenmark Pharmaceuticals Company Information
  51. 8.9.2 Glenmark Pharmaceuticals Business Overview
  52. 8.9.3 Glenmark Pharmaceuticals Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Glenmark Pharmaceuticals Nuclear Receptor ROR Gamma Product Portfolio
  54. 8.9.5 Glenmark Pharmaceuticals Recent Developments
  55. 8.10 Genfit SA
  56. 8.10.1 Genfit SA Company Information
  57. 8.10.2 Genfit SA Business Overview
  58. 8.10.3 Genfit SA Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Genfit SA Nuclear Receptor ROR Gamma Product Portfolio
  60. 8.10.5 Genfit SA Recent Developments
  61. 8.11 Eurofins Advinus
  62. 8.11.1 Eurofins Advinus Company Information
  63. 8.11.2 Eurofins Advinus Business Overview
  64. 8.11.3 Eurofins Advinus Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Eurofins Advinus Nuclear Receptor ROR Gamma Product Portfolio
  66. 8.11.5 Eurofins Advinus Recent Developments
  67. 8.12 Celgene Corp
  68. 8.12.1 Celgene Corp Company Information
  69. 8.12.2 Celgene Corp Business Overview
  70. 8.12.3 Celgene Corp Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Celgene Corp Nuclear Receptor ROR Gamma Product Portfolio
  72. 8.12.5 Celgene Corp Recent Developments
  73. 8.13 Bristol-Myers Squibb Company
  74. 8.13.1 Bristol-Myers Squibb Company Company Information
  75. 8.13.2 Bristol-Myers Squibb Company Business Overview
  76. 8.13.3 Bristol-Myers Squibb Company Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Bristol-Myers Squibb Company Nuclear Receptor ROR Gamma Product Portfolio
  78. 8.13.5 Bristol-Myers Squibb Company Recent Developments
  79. 8.14 Brickell Biotech Inc
  80. 8.14.1 Brickell Biotech Inc Company Information
  81. 8.14.2 Brickell Biotech Inc Business Overview
  82. 8.14.3 Brickell Biotech Inc Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Brickell Biotech Inc Nuclear Receptor ROR Gamma Product Portfolio
  84. 8.14.5 Brickell Biotech Inc Recent Developments
  85. 8.15 Aurigene Discovery Technologies
  86. 8.15.1 Aurigene Discovery Technologies Company Information
  87. 8.15.2 Aurigene Discovery Technologies Business Overview
  88. 8.15.3 Aurigene Discovery Technologies Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Aurigene Discovery Technologies Nuclear Receptor ROR Gamma Product Portfolio
  90. 8.15.5 Aurigene Discovery Technologies Recent Developments
  91. 8.16 AbbVie Inc
  92. 8.16.1 AbbVie Inc Company Information
  93. 8.16.2 AbbVie Inc Business Overview
  94. 8.16.3 AbbVie Inc Nuclear Receptor ROR Gamma Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AbbVie Inc Nuclear Receptor ROR Gamma Product Portfolio
  96. 8.16.5 AbbVie Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nuclear Receptor ROR Gamma Value Chain Analysis
  2. 9.1.1 Nuclear Receptor ROR Gamma Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nuclear Receptor ROR Gamma Sales Mode & Process
  6. 9.2 Nuclear Receptor ROR Gamma Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nuclear Receptor ROR Gamma Distributors
  9. 9.2.3 Nuclear Receptor ROR Gamma Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst